Communiqués CSL Limited

Actions

CSL

AU000000CSL8

Produits pharmaceutiques

Temps Différé Australian S.E. 04:24:06 14/09/2026			Varia. 5j.	Varia. 1 janv.
170,26 ^AUD	+1,89 %		-1,70 %	-1,40 %

04:39	Point sectoriel à la mi-journée sur l'ASX : progression de la santé, repli du secteur des matériaux	MT
03:34	La Bourse australienne progresse légèrement, portée par la santé et la consommation de base	RE

Communiqués

11/09	CSL : Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults	PU
01/09	CSL : Enters Agreements with the U.S. Government to Lower Drug Prices and Support Investment in U.S. Manufacturing	PU
06/08	CSL : European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries	PU
26/06	CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union	AQ
20/05	CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada	AQ
13/05	CSL : Published Large U.S. Study Finds Comparable Effectiveness Between Adjuvanted and High-Dose Influenza Vaccines in Adults 65 Years and Older	PU
12/05	CSL : Seqirus Signs Long-Term Agreement with the Pan American Health Organization (PAHO) to Advance Pandemic Influenza Preparedness in Latin America and the Caribbean	PU
17/03	Our Commitment to the Hemophilia B Community: An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Availability	PU
11/03	CSL Seqirus Signs Long-Term Agreement with The Pan American Health Organization to Advance Regional Influenza Protection in the Region of the Americas	AQ
10/03	CSL : Seqirus Signs Long-Term Agreement with The Pan American Health Organization (PAHO) to Advance Regional Influenza Protection in the Region of the Americas	PU
05/03	CSL : Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract	PU
16/02	CSL : Neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia	PU
10/02	CSL : Half Year Results Investor Presentation	PU
10/02	CSL : Half Year Results Announcement	PU
18/11	CSL : to invest approximately $1.5b in U.S. to manufacture plasma-derived therapies	PU
30/10/25	CSL : Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing of cell-based seasonal and pandemic influenza vaccines	PU
27/10/25	CSL : 2025 AGM Chair and CEO Speech and Presentation	PU
27/10/25	CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering	AQ
21/10/25	Enhanced Influenza Vaccines Provide Essential Protection for Older Adults: CSL Seqirus Presents New Evidence Supporting Broader Adoption Across Europe	PU
20/10/25	CSL Seqirus Presents Latest Research across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025	AQ
17/10/25	CSL : Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025	PU
17/10/25	CSL : near-term emissions reduction targets validated by the SBTi	PU
06/10/25	CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B	AQ
17/09/25	CSL : Notice of Meeting and Shareholder Pack	PU
19/08/25	CSL : Annual Report 2025	PU